LumiraDx Limited Warrant
LMDXW
LMDXW was delisted on the 8th of January, 2024.
1 hedge funds and large institutions have $2 invested in LumiraDx Limited Warrant in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $72.8K → $2 (-$72.8K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVS Health
Woonsocket,
Rhode Island
|
-$72.8K |
LMDXW Hedge Fund Activity: Q3 2024 in Review
1 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in LumiraDx Limited Warrant (LMDXW) for Q3 2024, worth a combined $2 — down 100% from $72.8K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LMDXW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was CVS Health, exiting entirely with an estimated $72.8K sold.
- 1 institutional investor held LumiraDx Limited Warrant (LMDXW) as of Q3 2024, down from 2 in Q2 2024.
- Funds reported $2 of LumiraDx Limited Warrant stock for Q3 2024, down 100% quarter-over-quarter.
- 0 funds opened new LumiraDx Limited Warrant positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest LumiraDx Limited Warrant seller in Q3 2024 was CVS Health, an estimated $72.8K sold.
Based on aggregated 13F filings for Q3 2024.